Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful conscientiously but unsuccessfully to produce an one off therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is actually an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination treatment in the healing of multi-drug-resistant HIV have been closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my last several shares. My 1st CytoDyn article, “CytoDyn: What In order to Do When It’s Too Good In order to Be True?”, set out what follows prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan offered such a highly marketing picture in the Uptick Newswire employment interview that I came away with a bad opinion of the business.

Irony of irony, my poor opinion of the business has grown steadily, however, the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger at the moment still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the therapy and prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of this expertise and also linked intellectual property coming from Progenics to CytoDyn, as well as approximately twenty five million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 zillion) as well as the very first brand new drug application endorsement ($5 million), as well as royalty payments of five percent of net sales after commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to get a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and many therapies, it’s this single therapy as well as a “broad pipeline of indications” since it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely beneficial therapy in dozens of indications.

The opening banner of its on its site (below) shows an energetic company with diverse interests albeit centered on leronlimab, several disease sorts, multiple presentations in addition to multiple publications.

Might all of it be smoke and mirrors? That’s a question I’ve been asking myself through the really beginning of the interest of mine in this particular business. Judging by the multiples of a huge number of several responses on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this question.

CytoDyn is a traditional battleground, or even some could say cult stock. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *